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Background: Targeted therapies in metastatic renal cell carcinoma (mRCC) have been approved based on registration
clinical trials that have strict eligibility criteria. The clinical outcomes of patients treated with targeted agents but are ineli-
gible for trials are unknown.
Patients and Methods: mRCC patients treated with vascular endothelial growth factor-targeted therapy were retro-
spectively deemed ineligible for clinical trials (according to commonly used inclusion/exclusion criteria) if they had a
Karnofsky performance status (KPS) <70%, nonclear-cell histology, brain metastases, hemoglobin ≤9 g/dl, creatinine
>2× the upper limit of normal, corrected calcium ≥12 mg/dl, platelet count of <100 × 103/uL, or neutrophil count <1500/mm3.
Results: Overall, 768 of 2210 (35%) patients in the International Metastatic RCC Database Consortium (IMDC) were deemed
ineligible for clinical trials by the above criteria. Between ineligible versus eligible patients, the response rate, median progres-
sion-free survival (PFS) and median overall survival of ﬁrst-line targeted therapy were 22% versus 29% (P= 0.0005), 5.2 versus
8.6 months, and 12.5 versus 28.4 months (both P< 0.0001), respectively. Second-line PFS (if applicable) was 2.8 months in
the trial ineligible versus 4.3 months in the trial eligible patients (P= 0.0039). When adjusted by the IMDC prognostic categories,
the HR for death between trial ineligible and trial eligible patients was 1.55 (95% conﬁdence interval 1.378–1.751, P< 0.0001).
Conclusions: The number of patients that are ineligible for clinical trials is substantial and their outcomes are inferior.
Speciﬁc trials addressing the unmet needs of protocol ineligible patients are warranted.
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introduction
In the past decade, there has been a marked shift in the treat-
ment and outcome of patients with metastatic renal cell carcin-
oma (mRCC). The understanding of the molecular changes
associated with mRCC has led to the development of multiple
new agents which largely target the vascular endothelial growth
factor (VEGF) and mammalian target of rapamycin (mTOR)
pathways. The initial targeted agents including sorafenib,
sunitinib, bevacizumab, and temsirolimus moved quickly from
the preclinical setting into phase I, II, and III clinical trials. The
data from these pivotal phase III clinical trials led to the rapid
approval of these agents [1–5]. Further trials have resulted in the
approval of other agents in both the ﬁrst- and second-line
setting including pazopanib, axitinib, and everolimus [6–8]. The
positive outcome from these large, well-conducted phase III
clinical trials has led to major changes in the way we manage
mRCC worldwide.
However, it is well known that there are strict criteria for clin-
ical trial eligibility for safety reasons and to maintain internal
validity and patient homogeneity within the clinical trial. The
‘everyday’ patient in routine clinical practice may not meet these
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criteria. This begs the question as to whether patients in the ‘real
world’ behave in a similar manner to those highly selected
patients on clinical trials. The question of generalizability to the
entire mRCC patient population arises.
The objective of this study was to review the clinical outcome
of a contemporary cohort of patients managed with VEGF-
targeted therapy and determine whether these patients would
have been eligible for clinical trials with targeted therapy (trial
eligible) or if they would never have been able to participate in
clinical trials (trial ineligible). Secondary objectives were to
compare the outcomes of trial eligible patients with those
deemed potentially trial ineligible.
patients andmethods
study population
The study population includes patients in the International Metastatic RCC
Database Consortium (IMDC) who were treated with contemporary VEGF-
targeted therapy, as their ﬁrst-line targeted therapy. This Consortium
includes consecutive, population-based patient samples from 2005 to 2011 at
19 international cancer centers from Canada, United States of America,
South Korea, Japan, Singapore, and Denmark. Patients initially treated with
mTOR inhibitors were excluded since the initial landmark trial with temsir-
olimus speciﬁcally looked at a poorer risk population of patients and had
generally different eligibility criteria (such as the including of patients with
nonclear-cell histology) than the VEGF-targeted therapy trials [5]. Patients
may have been treated on clinical trial or off protocol and may have been
treated at major academic centers or community oncology centers. Baseline
patient characteristics and outcome data were collected using uniform data
collection templates. Demographic, prognostic factor, and outcome data
were collected. Nonclear-cell carcinoma was ascertained when clear-cell hist-
ology was not the predominant subtype. Regulatory approval from local in-
stitutional review boards or research ethic boards was obtained for each
center.
eligible versus ineligible patients
Patients were retrospectively deemed ineligible for clinical trials according to
commonly used inclusion/exclusion criteria found in the phase III registra-
tion trials. The major exclusion criteria were as follows:
• Karnofsky performance status (KPS) <70%
• Nonclear-cell histology
• Brain metastases
• Hemoglobin ≤9 g/dl
• Creatinine >2 × upper limit of normal (ULN)
• Corrected calcium ≥12 mg/dl
• Platelet count <100 × 103/µl
• Neutrophil count <1500/mm2
If patients had any one or more of these exclusion criteria, they were con-
sidered trial ineligible. If patients had missing data on some of these para-
meters, they were still deemed trial ineligible if they fulﬁlled one or more of
these exclusion criteria. If patients had missing data on one or more para-
meters but were trial eligible for all other parameters, they were considered
trial eligible to provide the most conservative estimate of eligibility. A sensi-
tivity analysis categorizing these patients with missing data as trial ineligible
was also carried out which revealed similar outcomes. All other patients
were assumed to be potentially eligible for the clinical trials.
statistics
Descriptive statistics were generated and compared using χ2 tests for propor-
tions and t-tests for means. Response rates were deﬁned by the proportion of
patients with best response as partial responses (PR) or complete responses
(CR) by RECIST 1.0 criteria out of the overall population [9]. Patients with
progressive disease or stable disease were classiﬁed as nonresponders. First-
line progression-free survival (PFS) was deﬁned as time from ﬁrst VEGF-
targeted therapy drug initiation to progression, death, drug cessation, or
censored at the last follow-up. Second-line PFS was deﬁned as time from ini-
tiation of second targeted therapy drug to progression, death, drug cessation,
or censored at the last follow-up. Overall survival (OS) was deﬁned as time
from ﬁrst-line targeted therapy drug initiation to death or censored at the
last follow-up. Kaplan–Meier curves were constructed and log-rank tests
were carried out to compare ﬁrst-line PFS, second-line PFS, and OS in trial
eligible versus ineligible patients. Proportional hazards regression was
carried out to OS hazard ratio (HR) estimates by patient prognostic groups
according to the IMDC criteria [10, 11]. The case deletion method was used
to handle missing data. All analyses were carried out on SAS 9.2 (SAS
Institute, Inc., Cary, NC).
results
Overall, 2210 patients with mRCC treated with VEGF-targeted
therapy were included in this analysis. As shown in Figure 1,
768 (35%) of patients were deemed trial ineligible and 1442
(65%) were deemed trial eligible. The most common ﬁrst-line
therapy was sunitinib, followed by sorafenib, bevacizumab, and
pazopanib. Two patients received axitinib as part of a clinical
trial and were appropriately deemed trial eligible.
There were multiple reasons why patients were deemed ineli-
gible as shown in Table 1. The most common reason was
Karnofsky performance status (KPS) <70% in 13% of patients,
nonclear histology in 11%, brain metastases in 8%, and low
hemoglobin (≤9) in 8%. The majority of patients (605) were
excluded due to one exclusion criteria while 140 patients met
two exclusion criteria and one patient had ﬁve exclusion criteria
as shown in Table 2.
The baseline patient demographics are shown in Table 3 for
all patients, ineligible patients, and eligible patients. There was
no difference in the median age between the two groups. In
terms of all other baseline demographic data, the ineligible
group had poorer prognostic proﬁles (P < 0.0001) and fewer
nephrectomies (P < 0.0001). By deﬁnition, patients in the trial
ineligible group had lower KPS, more anemia, hypercalcemia,
brain metastases, and nonclear-cell histology.
2210
Patients with mRCC treated with 
targeted therapy
768 (35%)
“INELIGIBLE PATIENTS”
Sunitinib = 591
Sorafenib = 146
Bevacizumab = 24
Pazopanib = 7
Axitinib = 0
1442 (65%)
“ELIGIBLE PATIENTS”
Sunitinib = 1038
Sorafenib = 312
Bevacizumab = 76
Pazopanib = 14
Axitinib = 2
Figure 1. Trial ineligible and eligible patients.
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patient outcomes
Response rates are based on 1790 patients who had data on
RECIST 1.0 response rates (RR). Overall, 27% of patients had an
objective response (CR + PR). In trial ineligible patients, the re-
sponse rate was only 22% compared with trial eligible patients
where it was 29% (P = 0.0005) as shown in Table 4. When
looking at the favorable, intermediate, and poor risk patients
according to the IDMC criteria, the intermediate and poor risk
ineligible patients had a lower response rate than the eligible
patients. In the favorable risk patients, response rates were
similar (38% in ineligible and 34% in eligible, P = 0.62) but this
may be due to smaller patient numbers or that patients with fa-
vorable risk usually have better outcomes irrespective of trial eli-
gibility status.
The PFS of ﬁrst-line VEGF targeted therapy in ineligible
patients was lower than that of the eligible patients (5.0 versus
8.6 months, P < 0.0001) as shown in Figure 2A. The PFS with
second-line targeted therapy in ineligible patients was also less
than those of eligible patients (2.8 versus 4.3 months,
P = 0.0039) as shown in Figure 2B. The OS in ineligible patients
was 12.5 months compared with 28.4 months in the eligible
patients (P < 0.0001) as shown in Figure 2C. Patients who were
excluded due to KPS <70, hemoglobin ≤9 g/dl, calcium ≥12
mg/dl, brain metastases, and nonclear-cell histology had a HR
for death of 3.1 [95% conﬁdence interval (CI) 2.7–3.6], 2.4 (95%
CI 2.0–2.9), 2.7 (95% CI 1.9–3.8), 1.5 (95% CI 1.2–1.7), and 1.4
(95% CI 1.1–1.6), respectively (all P < 0.01) on univariable ana-
lysis. The other exclusion criteria did not statistically signiﬁ-
cantly affect OS.
Table 3. Baseline patient characteristics
Parameter Ineligible (N = 768) Eligible (N = 1442)
Age (median, years) 60 (N = 768) 61 (N = 1442)
IMDC prognostic category
Favorable 9% (65/688) 24% (297/1217)
Intermediate 48% (329/688) 59% (721/1217)
Poor 43% (294/688) 16% (199/1217)
KPS (median, range) 80 (range 20–100) (n = 746) 90 (range 70–100) (n = 1365)
Anemia (below LLN) 70% (518/741) 52% (698/1333)
Hypercalcemia (above ULN) 15% (111/717) 6% (82/1290)
Brain metastases present 24% (182/765) 0% (0/1433)
Nonclear-cell histology 32% (230/727) 0% (0/1341)
Prior nephrectomy 72% (552/768) 83% (1192/1440)
Table 4. First-line response rates (RR)
IMDC prognostic group All available patients RR Eligibility status P-value comparing ineligible
to eligible patientsIneligible RR Eligible RR
All patients (N = 1790)* 27% (481/1790) 22% (129/594) 29% (352/1196) 0.0005
Favorable (N = 309) 35% (107/309) 38% (21/56) 34% (86/253) 0.6176
Intermediate (N = 885) 28% (252/885) 24% (65/274) 31% (187/611) 0.0359
Poor (N = 372) 20% (73/372) 15% (32/209) 25% (41/163) 0.0177
*Patients in risk groups do not add up to 1790 because not all patients had prognostic group and response rate data available.
Table 2. Number of exclusion criteria met in patients
Number of exclusion criteria met Number of patients
0 1442
1 605
2 140
3 19
4 3
5 1
Total 959 exclusion criteria met
in 768 patients
Table 1. Number of patients excluded due to each exclusion criteria
Exclusion parameter Number of patients excluded
due to this parameter/patients
with available data (%)
KPS <70% 274/2111 (13)
Nonclear-cell histology 230/2068 (11)
Brain metastases 182/2198 (8)
Hemoglobin ≤9 g/dl 156/2074 (8)
Creatinine >2× ULN 38/1607 (2)
Corrected calcium ≥12 mg/dl 38/2007 (2)
Platelet count of <100 × 103/uL 28/2068 (1)
Neutrophil count <1500/mm3 13/1997 (<1)
Total 959 exclusion criteria
met in 768 patients
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Figure 2. (A) Median PFS from ﬁrst-line targeted therapy was 5.0 versus 8.6 months (P < 0.0001) in the trial ineligible versus trial eligible patients. (B) Median
PFS from second-line targeted therapy was 2.8 versus 4.3 months (P = 0.0039) in the trial ineligible versus trial eligible patients. (C) Median overall survival
from ﬁrst-line targeted therapy was 12.5 versus 28.4 months (P < 0.0001) in the trial ineligible versus trial eligible patients.
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When adjusted by the IMDC prognostic criteria, the HR for
death between the trial ineligible versus trial eligible patients
was 1.55 (95% CI 1.378–1.751, P < 0.0001). The HR for PFS
from initiation of ﬁrst-line therapy was 1.32 (95% CI 1.19–1.46).
These results were very similar if adjusted by the MSKCC prog-
nostic criteria.
discussion
Well-conducted clinical trials are essential for the development
of new treatment advances that prolong OS in cancer. Despite
this, <5% of all cancer patients are enrolled in clinical trials
and we often use these results to generalize our treatment deci-
sions to all patients seen in cancer centers around the world
(http://www.cancer.gov/clinicaltrials/conducting/boosting-trial-
participation/Page3).
To our knowledge, this is the largest study of its kind to dem-
onstrate that, in the real world, 35% of mRCC patients would
not have met the eligibility criteria for VEGF-targeted therapy
clinical trials based on routine exclusion criteria. This high per-
centage translates into a large number of patients given therapy
based on data that do not apply to them. It is not surprising that
the two most common reasons for ineligibility were a lower KPS
and nonclear-cell histology. Many ‘real-world’ patients are more
ill than those on clinical trials, often on the basis of disease
burden. It is common for clinicians to extrapolate data from
clinical trials to sicker patients with poorer prognostic factors in
order to try to improve patient survival.
Most of the VEGF-targeted therapy phase III clinical trials
did not allow nonclear-cell histology, given the VEGF pathway
may not be the optimal target in these patients, based on the
biology of this disease around VHL inactivation. Unfortunately,
the optimal therapy for nonclear-cell RCC is still unknown and,
thus, it is not surprising that many of these patients received
VEGF-targeted therapy.
Trial ineligible patients had a worse outcome in terms of RR,
PFS, and OS with the adjusted HR for death about 1.55 for ineli-
gible versus eligible patients. For the trial eligible patients, the
PFS of 8.6 months and the OS of 28.4 months in our study are
similar to the outcomes reported in the pivotal phase III trial
comparing Suntinib to Interferon where the PFS for sunitinib-
treated patients was 11.0 months and the OS of 26.4 months
[12]. In the trial ineligible patients, the PFS of 5.0 months and
the OS of 12.5 months appear much worse than the pivotal
phase III trial as well as the Expanded Access trial patients where
the PFS was 10.9 months and the OS was 18.4 months [13].
Worse outcomes for patients not fulﬁlling trial eligibility cri-
teria have also recently been reported in a smaller study of stage
IV colorectal cancer patients [14]. Patients in the Netherlands
receiving standard chemotherapy on a clinical trial were com-
pared with those receiving the exact same treatment off a clinical
trial. In this study of the 396 patients treated off trial, 85 (21.5%)
did not meet the eligibility criteria. Worse PS, elevated alkaline
phosphatase, and less resected primary tumors were the reasons
for trial ineligibility. These patients had a worse OS compared
with eligible nontrial patients (9.3 versus 15.7 months, P < 0.01).
The authors conclude that trial results do have external validity,
provided that standard eligibility criteria are observed and argue
against the use of cancer treatments in patients that would not
have been eligible. Other studies have shown that outcomes of
patients treated off clinical trials are worse than those treated on
clinical trials although there may be various reasons the patient
was not enrolled on to a clinical trial other than ineligibility,
such as patient preference [15].
Strengths of this study include its large patient population and
the use of consecutive population-based series to prevent selec-
tion bias. Additionally, it reﬂects real-world treatment practice
patterns as opposed to those tightly regulated by clinical trial pro-
tocols. Limitations of this study include the retrospective nature
of the data collection. Not all the inclusion/exclusion criteria that
would be in a formal phase III study were collected (concomitant
medications, RECIST nonmeasurable disease, etc.). Thus, the
number in this study may actually be an underestimate of the
number of trial ineligible patients. The RECIST RR were deter-
mined by the investigators and not a central blinded reviewer but
this was similar in both the eligible and ineligible patients and
adds to the generalizability of the study as it reﬂects everyday clin-
ical practice. There were missing data in determining each
patient’s eligibility status; thus, a sensitivity analysis was carried
out categorizing those patients with too much missing data
without any obvious exclusionary criteria as trial ineligible. This
raised the trial ineligible group to 43% (959 of 2210) but all of the
RR, PFS, and OS outcomes and, most importantly, the HR for
death were very similar to the results presented.
Clinical trials to test new drugs and improve outcomes are im-
perative in oncology. It is important for clinicians to remember
that data from clinical trials cannot universally be extrapolated
to the real-world patients and that these discrepancies in clinical
outcomes should be taken into account when discussing treat-
ment options and outcomes with individual patients. That being
said, the outcomes of the trial ineligible mRCC patients reported
here are still an improvement compared with outcomes in the
era of nontargeted therapy. Patients deemed trial ineligible may
potentially beneﬁt from targeted therapy, but outcome expecta-
tions may need to be tempered.
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A cohort study investigating aspirin use and survival
in men with prostate cancer
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Background: Aspirin use has been associated with reduced mortality from cancer including prostate cancer in some
studies. A number of anti-cancer mechanisms of aspirin have been proposed, including the inhibition of the cyclooxygen-
ase enzymes, through which aspirin mediates both anti-platelet and anti-inﬂammatory activities. This cohort study
examines associations between pre-diagnostic aspirin use (overall and by dose and dosing intensity) and mortality in men
with localised prostate cancer.
Patients and methods: Men with stage I–III prostate cancer were identiﬁed from Irish National Cancer Registry
records, which have been linked to national prescribing data from the Irish General Medical Services scheme. Aspirin use
in the year preceding prostate cancer diagnosis was identiﬁed from this linked prescription-claims data. Adjusted hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were estimated for associations between aspirin use and all-cause and
prostate cancer-speciﬁc mortality. Associations between prescribed dose and dosing intensity were examined. The pres-
ence of effect modiﬁcation by the type of treatment received and tumour characteristics was also assessed.
Results: Two thousand nine hundred and thirty-six men with a diagnosis of stage I–III prostate cancer (2001–2006) were
identiﬁed (aspirin users, n = 1131). The median duration of patient follow-up was 5.5 years. In adjusted analyses, aspirin
use was associated with a small, but non-signiﬁcant, reduced risk of prostate cancer-speciﬁc mortality (HR = 0.88, 95% CI
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